Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYO7VH)

• Drug Name: PMID25416646-Compound-Figure5-E Drug Info
• Cross-matching ID: TTD Drug ID: DMYO7VH

Molecule-Related Drug Atlas

Drug(s) Targeting Angiotensin II receptor type-2 (AGTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ANGIOTENSIN II	DMLWQ27	Increase blood pressure	BA04	Approved	[2]
SARALASIN	DMKS1DV	Hypertension	BA00-BA04	Approved	[3]
EMA-401	DMYOUB6	Peripheral neuropathy	8C0Z	Phase 2	[4]
MP-157	DM5VXWO	Hypertension	BA00-BA04	Phase 1	[5]
Phenylpyridine derivative 3	DMDT5JI	N. A.	N. A.	Patented	[1]
1-(biphenyl-4-yl-methyl)-1H-imidazole derivative 1	DMGYZQ2	N. A.	N. A.	Patented	[1]
Fonsartan	DM15LAP	Hypertension	BA00-BA04	Discontinued in Phase 2	[6]
L-158282	DMKSEIY	N. A.	N. A.	Discontinued in Phase 2	[7]
TAK-591	DM25DB4	Hypertension	BA00-BA04	Discontinued in Phase 1	[8]
L-159689	DM9JE7Y	Hypertension	BA00-BA04	Terminated	[9]

Drug(s) Targeting Peroxisome proliferator-activated receptor gamma (PPAR-gamma)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[10]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[11]
Lobeglitazone	DMHY3IP	Type-2 diabetes	5A11	Approved	[12]
Rosiglitazone XR	DMT45MU	Type-2 diabetes	5A11	Approved	[13]
Thiazolidinedione	DMC1NBW	Alzheimer disease	8A20	Approved	[11]
Glitazone	DMDN4A1	N. A.	N. A.	Phase 4	[14]
MURAGLITAZAR	DMG3NFZ	N. A.	N. A.	Phase 3	[15]
Rivoglitazone	DMBY31K	Ocular inflammation	9C61.24	Phase 3	[16]
Balaglitazone	DMXBHR6	Type-1 diabetes	5A10	Phase 3	[17]
Ragaglitazar	DMFSHEM	Type-1 diabetes	5A10	Phase 3	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Angiotensin II receptor type-2 (AGTR2)	TTQVOEI	AGTR2_HUMAN	Agonist	[1]
Peroxisome proliferator-activated receptor gamma (PPAR-gamma)	TTZMAO3	PPARG_HUMAN	Agonist	[1]

References

• [1] PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
• [2] The preparation of (perfluoroalkyl)imidazoles as nonpeptide angiotensin II receptor antagonists, Bioorg. Med. Chem. Lett. 3(5):895-898 (1993).
• [3] cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
• [4] Clinical pipeline report, company report or official report of Spinifex.
• [5] As drug target reemerges, the question is to block or stimulate it. Nature Medicine. Spoonful of Medicine. 05 Feb 2014. Cassandra Willyard
• [6] Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens. 1998 Dec;16(12 Pt 2):2039-43.
• [7] Subtituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors, Bioorg. Med. Chem. Lett. 4(1):189-194 (1994).
• [8] Clinical pipeline report, company report or official report of Takeda (2009).
• [9] The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists, Bioorg. Med. Chem. Lett. 6(8):923-928 (1996).
• [10] Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 2003 May 1;104(5):597-602.
• [11] Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med. 2002 Nov;8(11):1281-7.
• [12] Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
• [13] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [14] Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
• [15] Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
• [16] A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806-13.
• [17] Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist.Mini Rev Med Chem.2012 Feb;12(2):87-97.
• [18] Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.